Last Updated : March 24, 2023
Details
FilesProject Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HD0011-000
Effective finish date:
Biologics require formulary management strategies upon loss of exclusivity (i.e., data protection and/or patent expiry) to manage expenditures due to a lack of or delay in biosimilar development and market approval. Several old-generation biologics used to treat plaque psoriasis have lost exclusivity but represent a significant portion of expenditures. These biologics often predate pan-Canadian Pharmaceutical Alliance (pCPA) agreements, whereas new-generation biologics, which have head-to-head evidence versus old-generation biologics, have negotiated prices under pCPA agreements. This warrants a health technology management approach to assess the appropriate use of biologics in plaque psoriasis, which could improve patient outcomes and manage drug expenditures.
Files
Last Updated : March 24, 2023